Boundless Bio Revenue and Competitors

Location

#3269

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Boundless Bio's estimated annual revenue is currently $14.6M per year.(i)
  • Boundless Bio's estimated revenue per employee is $155,000
  • Boundless Bio's total funding is $151.4M.

Employee Data

  • Boundless Bio has 94 Employees.(i)
  • Boundless Bio grew their employee count by 11% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$1.1M70%N/AN/A
#4
$2.3M15150%N/AN/A
#5
$1.4M90%N/AN/A
#6
$11.5M74-12%N/AN/A
#7
$0.4M27510%$236.7MN/A
#8
$4M51-74%$160MN/A
#9
$2.5M1633%N/AN/A
#10
$3.3M21-12%N/AN/A
Add Company

Boundless Bio, a San Diego based company backed by ARCH Venture Partners, is discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence. When DNA in cancer cells comes off chromosomes, ᅢᄁ¬ツᆲᅤモextrachromosomal DNA (ecDNA),ᅢᄁ¬ツᆲᅡン it becomes unbound and unwound, thereby enabling numerous copies of cancer-causing genes, driving cancer cells to grow and allowing them to resist treatment. At Boundless Bio, we are counterattacking this ecDNA phenomenon with boundless innovation and boundless energy to develop powerful new cancer medicines that eliminate cancer cellsᅢᄁ¬ツᆲ¬トᄁ ability to employ ecDNA to survive. More information coming soon. Career Inquiries careers@boundlessbio.com General Information Inquiries info@boundlessbio.com

keywords:N/A

$151.4M

Total Funding

94

Number of Employees

$14.6M

Revenue (est)

11%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Boundless Bio News

2022-04-06 - Boundless Bio Presents Data on the Novel Discovery of the ...

Boundless Bio previously demonstrated that cancers with oncogenes ... a novel area of cancer biology, extrachromosomal DNA (ecDNA),...

2021-05-24 - Boundless Bio Raises $105 Million Series B Financing

Boundless Bio ... Take 1 minute to subscribe and you'll get this story immediately, plus: Already a subscriber? Sign in 52 weekly issues Subscriber-only digital content every business day, plus full access to SDBJ.com archives Book of Lists — the most comprehensive business resource in San Di ...

2021-04-28 - Boundless Bio Picks Up $105M

San Diego-based Boundless Bio, a company developing therapeutics for treating cancer, has raised $105M in its Series B funding, the company said this morning. According to the company, the funding was led by Nextech invest and RA Capital Management, and also included new investors Fidelity Manag ...

2021-04-28 - Boundless Bio : Raises Oversubscribed $105 Million Series B Financing to Advance Next-Generation Precision Oncology Therapies Directed Against Extrachromosomal DNA (ecDNA)

Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced the closing of an oversubscribed $105 Million Series B financing. With the proceeds of the financing, the company wi ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$28.9M9416%N/A
#2
$23.9M94N/AN/A
#3
$25.4M9421%N/A
#4
$25.4M9421%N/A
#5
$35M9462%N/A